Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 206-117-5 | CAS number: 302-17-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Repeated dose toxicity: oral
NOAEL was considered to be 14.4 mg/kg bw/day in male mice when exposed to Chloral Hydrate for 14 days by (oral) gavage.
Repeated dose toxicity: inhalation
Data available for acute toxicity by the inhalation route does not indicate inhlation toxicity in short term study. Also according to Annex IX of the REACH regulation, testing by the inhalation route is appropriate only if exposure of humans via inhalation is likely. Taking intoaccount the particle size distribution of the substance the majority of the particles were found to be in the size of 150 micrometer which is much larger size range compared to the inhalable particulate matter. Thus, exposure to inhalable dust, mist and vapour of the chemical chloral hydrate is highly unlikely. Therefore this study is considered for waiver.
Repeated dose toxicity: dermal
The acute toxicity value for chloral hydrate(as provided in section 7.2.3) is >2000 mg/kg body weight. Also considering the use of chloral hydrate as a medicine for sedation/hypnotic adverse effect by repeated exposure by the dermal route is highly unlikely. In addition, there is no data available that suggests that chloral hydrate shall exhibit repeated dose toxicity by the dermal route. Hence this end point was considered for waiver.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Justification for type of information:
- Data is from peer-reviewed open access journal
- Qualifier:
- according to guideline
- Guideline:
- other: as mentioned below
- Principles of method if other than guideline:
- In range finding Study the toxic effect of Chloral Hydrate was observed in CD1-male mice for 14 days by gavage.
- GLP compliance:
- not specified
- Specific details on test material used for the study:
- - Name of test material: 2,2,2-Trichloroethane-1,1-diol (Chloral hydrate)
- Molecular formula: C2-H3-Cl3-O2
- Molecular weight: 165.4026g/mol
- Smiles notation: C(C(O)O)(Cl)(Cl)Cl
- InChl: RNFNDJAIBTYOQL-UHFFFAOYSA-N
- Substance type: Organic
- Physical state: Solid - Species:
- mouse
- Strain:
- CD-1
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories, Wilmington, MA.
- Age at study initiation: 6 week old mice.
- Weight at study initiation: 25.1 ± 0.2 to 25.5 ± 0.2 g
- Fasting period before study: No data available.
- Housing: Mice were housed four per cage in plastic shoebox cages containing sawdust bedding (PWI Hardwood Sawdust, Lowville, N.Y.). Identified by ear punching
- Diet (e.g. ad libitum): Agway Lab Chow ad libitum
- Water (e.g. ad libitum): Deionized water, ad libitum
- Acclimation period: 1 week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21-24°C
- Humidity (%):40-60%
- Air changes (per hr): No data available
- Photoperiod (hrs dark / hrs light): 12-hr light/dark cycle
IN-LIFE DATES: From: To: No data available - Route of administration:
- oral: gavage
- Vehicle:
- other: Deionized water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: Chloral hydrate was diluted in deionized water in the concentrations of 14.4 and 144 mg/kg and administered by gavage in a volume of 0.01 ml/g body weight.
Drinking water solutions were maintained at room temperature in amber-colored bottles fitted with sipper spouts and was changed twice weekly.
VEHICLE
- Justification for use and choice of vehicle (if other than water): Deionized water
- Concentration in vehicle: 0, 14.4 and 144 mg/kg body weight/day
- Amount of vehicle (if gavage): 0.01 ml/g
- Lot/batch no. (if required): No data available
- Purity: No data available - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Dose was analysis by using GLC and head space analysis.
- Duration of treatment / exposure:
- 14 days
- Frequency of treatment:
- Daily
- Remarks:
- Doses / Concentrations:
0(control),14.4 and 144 mg/kg/bw/day
Basis:
no data - No. of animals per sex per dose:
- Total animals: 188
Control: 68 males
14.4 mg/kg/day: 60 males
144 mg/kg/day: 60 males - Control animals:
- yes, concurrent vehicle
- Details on study design:
- No data available
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily
- Cage side observations checked in table [No.?] were included: Mortality was observed.
DETAILED CLINICAL OBSERVATIONS: No data available
- Time schedule: No data available
BODY WEIGHT: Yes
- Time schedule for examinations: On day 1, 8 and 15 of treatment.
FOOD CONSUMPTION : No data available
COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes / No / No data
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data available
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No data: No data available
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study):
- Time schedule for examinations: No data available: No data available
OPHTHALMOSCOPIC EXAMINATION: No data available
- Time schedule for examinations:
- Dose groups that were examined:
HAEMATOLOGY: Yes,
- Time schedule for collection of blood: At the termination of study.
- Anaesthetic used for blood collection: Yes, chloroform was used.
- Animals fasted: No data available
- How many animals: All 188 animals were examined.
- Parameters checked in table [No.?] were examined: Hematocrit, Hemoglobin, Leukocytes, Fibrinogen and Prothombin time were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At the termination of study.
- Anaesthetic used for blood collection: Yes, chloroform was used.
- Animals fasted: No data available
- How many animals: All 188 animals were examined.
- Parameters checked in table [No.?] were examined: Lactic dehydrogenase, serum glutamic pyruvic transaminase, blood urea nitrogen were examined.
URINALYSIS: Yes
- Time schedule for collection of urine: At the termination of study.
- Metabolism cages used for collection of urine: No data available
- Animals fasted: No data available
- Parameters checked in table [No.?] were examined. No data available
NEUROBEHAVIOURAL
EXAMINATION: No data available
OTHER:
Organ weight: Yes
Organ examined: Brain, Liver, Spleen, Lungs, Thymus, Kidneys and Testes were examined. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes ,The organs (brain, liver, spleen, lungs, thymus, kidneys, and testes) were removed,trimmed, weighed, and gross pathological examinations were performed on all mice.
HISTOPATHOLOGY: No data available - Statistics:
- Statistical analysis is performed by using one-way analysis of variance, If a one-way analysis of variance of the means showed treatment effects; a Dunnett's T-test was performed. Values which differ from vehicle control at p < 0.05 are noted. Each of the values is given as the mean +standard error (SE) of the mean.
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- CLINICAL SIGNS:No data available
MORTALITY:One male mice from both 14.4 and 144 mg/kg body weight /day died on second week.
Death were probably not compound-related since two mice of control group were also died during 14 day treatment period.
BODY WEIGHT AND WEIGHT GAIN:No effect was observed on body weight and body weight gain of treated mice as compared to control.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):No data available
FOOD EFFICIENCY:No data available
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study):No data available
OPHTHALMOSCOPIC EXAMINATION:No data available
HAEMATOLOGY:No effect was observed on Hematological and coagulation values of treated mice as compared to control.
CLINICAL CHEMISTRY:When treated with 144 mg/kg body weight/day, statistically significant decreased in lacticdehydrogenase activity were observed in treated mice as compared to control.
URINALYSIS:No data available
NEUROBEHAVIOUR:No data available
ORGAN WEIGHTS:When treated with 144 mg/kg body weight/day, significant increased in absolute and relative liver weight and significant decreased in relative spleen weight were observed as compared to control.
When treated with 14.4 mg/kg body weight/day, decreased in relative kidneys weight was observed in treated mice as compared to control.
The observed changes for 14.4 mg/kg bw/day treated mice are not significantly different from control.
GROSS PATHOLOGY:Increase in liver size and decrease in spleen size were observed in 144 mg/kg bw/day treated mice as compared to control.
Changes were also observed in 14.4 mg/kg bw/day treated mice but the changes are not significantly different from control.
HISTOPATHOLOGY: NON-NEOPLASTIC:No data available - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 14.4 other: mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: No adverse effect on Body weight and weight gain, haematology, clinical chemistry, organ weights and gross pathology.
- Key result
- Critical effects observed:
- no
- Conclusions:
- NOAEL was considered to be 14.4 mg/kg bw/day in male mice when exposed to Chloral Hydrate for 14 days by (oral) gavage.
- Executive summary:
In repeated dose toxicity study, Random – bred CD1 male mice were exposed to Chloral Hydrate by oral gavage in the concentrations of 0 (control), 14.4 and 144 mg/kg//body weight/day.
Result shows statistically significant decreased in lactic dehydrogenase activity, increased in absolute and relative liver weight and significant decreased in relative spleen weight. In addition, Increase in liver size and decrease in spleen size was observed in 144 mg/kg bw/day treated mice as compared to control. Changes were also observed in organ weight and gross pathology of 14.4 mg/kg bw/day treated mice but the changes are not significantly different from control.
Therefore, NOAEL was considered to be 14.4 mg/kg body weight/day in male mice when exposed to Chloral Hydrate for 14 days by oral gavage.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 14.4 mg/kg bw/day
- Study duration:
- subacute
- Species:
- mouse
- Quality of whole database:
- K2 level data has been obtained from peer reviewed journal
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: inhalation
- Data waiving:
- other justification
- Justification for data waiving:
- other:
- Critical effects observed:
- not specified
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: dermal
- Data waiving:
- other justification
- Justification for data waiving:
- other:
- Critical effects observed:
- not specified
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Repeated dose oral:
No. of studies of Chloral hydrate were reviewed for repeated dose oral toxicity from reliable sources having Klimisch rating 2. The summary of the results are presented below:
In a key repeated dose toxicity study from Environmental Health Perspectives Vol. 44, pp. 137-146, 1982, Random – bred CD1 male mice were exposed to Chloral Hydrate by oral gavage in the concentrations of 0 (control), 14.4 and 144 mg/kg//body weight/day. Result shows statistically significant decreased in lactic dehydrogenase activity, increased in absolute and relative liver weight and significant decreased in relative spleen weight. In addition, Increase in liver size and decrease in spleen size was observed in 144 mg/kg bw/day treated mice as compared to control. Changes were also observed in organ weight and gross pathology of 14.4 mg/kg bw/day treated mice but the changes are not significantly different from control. Therefore, NOAEL was considered to be 14.4 mg/kg body weight/day in male mice when exposed to Chloral Hydrate for 14 days by oral gavage.
From same publication in a subchronic toxicity study, Random – bred CD-1 male and female mice were exposed to Chloral Hydrate in the concentration of 0, 0.07 and 0.7 mg/ml. Change in body weight and body weight gain, haematological and clinical parameters, change in relative weight of brain, lung and liver of male and female treated with 0.07 mg/ml as compared to control. In addition,increased hepatic microsomal aminopyrine N-demthylase and aniline hydroxylase activity and increased ctyochrome b5 content of male mice and aniline hydroxylase activity was increased, while liver nonprotein sulfhydryl and cytochrome b5 levels were decreased in female mice when treated with 0.07 mg/ml as compared to control. Therefore, LOAEL was considered to be 0.7 mg/ml (16 mg/kg/day for male and 18 mg/kg/day for female) when male and female Random – bred CD-1 mice were exposed to Chloral Hydrate orally in drinking water for 90 days.
Further in a Combined repeated and reproductive screening toxicity study from Reproductive Toxicology, Vol. 9, No. 6. pp. 571-578, 1995, F344 male rat were exposed to chloral hydrate in the concentration of 0, 55.0 and 188.0 mg/kg/day by oral drinking water. No significant effect were observed on clinical sign, body weight, organ weight, gross pathology and histopathology but significant decrease were observed in percentage of motile sperm (MOT) and percentage of progressively motile sperm (PMOT). In addition, Mean straight-line velocities average path and straight-line velocity distributions were shifted to a lower modal velocity range in 188.0 mg/kg/day reated rat as compared to control. The observed effect is on sperm parameters of treated rat. Therefore NOAEL was considered to be 55.0 mg/kg bw/day when F344 male rats were exposed to chloral hydrate on the basis of no significant effect were observed on clinical sign, body weight, organ weight, gross pathology, histopathology and effect on sperm parameters . While LOAEL was considered to be 188.0 mg/kg/day on the basis of significant decrease were observed in percentage of motile sperm (MOT) and percentage of progressively motile sperm (PMOT).
Based on the studies summarized above it can be observed that LOAEL value varies from 16 to 188 mg/kg/day in mice and rat respectively, whereas the no observed adverse effect value (NOAEL) value in mice is 14.4 and 55.0 mg/kg bw/day in mice and rat respectively. Also at any of the mentioned dose no significant effects on any target organ was observed. Thus the substance does not classify for repeated dose toxicity via the oral route.
Repeated dose toxicity: inhalation
Data available for acute toxicity by the inhalation route does not indicate inhlation toxicity in short term study. Also according to Annex IX of the REACH regulation, testing by the inhalation route is appropriate only if exposure of humans via inhalation is likely. Taking intoaccount the particle size distribution of the substance the majority of the particles were found to be in the size of 150 micrometer which is much larger size range compared to the inhalable particulate matter. Thus, exposure to inhalable dust, mist and vapour of the chemical chloral hydrate is highly unlikely. Therefore this study is considered for waiver.
Repeated dose toxicity: dermal
The acute toxicity value for chloral hydrate(as provided in section 7.2.3) is >2000 mg/kg body weight. Also considering the use of chloral hydrate as a medicine for sedation/hypnotic adverse effect by repeated exposure by the dermal route is highly unlikely. In addition, there is no data available that suggests that chloral hydrate shall exhibit repeated dose toxicity by the dermal route. Hence this end point was considered for waiver.
Justification for classification or non-classification
At any of the mentioned dose no significant effects on any target organ was observed. Thus the substance does not classify forrepeated dose toxicity via the oral route. Whereas the repeated dose toxicity by the inhalation and dermal route were considered for waivers.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
